Tag: diseases

Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors

Medical Opinion Concludes that Beyond Oil has Potential to Reduce Gastrointestinal Cancer Risk Among Consumers of Fried Foods and Food Service Workers

The global patient handling equipment market is set to grow from USD 12.4 billion in 2025 to USD 16.4 billion by 2030, at a CAGR of 5.8%. Key growth drivers include the aging population and rising prevalence of cardiovascular diseases, necessitating advanced and ergonomic devices. A surge in home healthcare services across North America, Europe, and Asia Pacific further boosts demand. The patient transfer devices segment, particularly patient lifts, dominates due to increasing awareness and musculoskeletal injuries among healthcare staff. The Asia Pacific region, driven by countries like China and India, is predicted to grow significantly. Leading companies include Arjo, Stryker, and Baxter International.

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.

Cardiff, United Kingdom – 18 June 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million) in the last nine months. The oversubscribed Series A financing was led by Access Biotechnology, with participation from Canaan Partners, SR One, Sanofi Ventures, Schroders Capital along with seed investors SV Health Investors, which co-founded the company, and ICG.